'Living drugs' target CD70 in advanced renal tumors

URN to cite this document:: urn:nbn:de:bvb:355-epub-591482
DOI to cite this document:: 10.5283/epub.59148

Wagner, Kilian ; Siska, Peter J.

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(278kB)

Date of publication of this fulltext: 12 Sep 2024 05:56

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.

Owner only: item control page

Download Statistics